New study reveals previously unknown cause of Alzheimer’s disease and dementia

New findings in Alzheimer’s disease and vascular dementia are uncovering a hidden mechanism of cell death, opening new paths for research and treatment.

Scientists at Oregon Health & Science University (OHSU) have identified ferroptosis—an iron-dependent form of cell death—as a major cause of microglia destruction.

Their study, published in Annals of Neurology, suggests that this overlooked process may play a crucial role in disease progression.

Microglia act as the brain’s immune defenders, keeping neural pathways clear of debris and responding to damage. Their work is particularly vital when myelin—the protective sheath around nerve fibers—suffers damage. Without functional microglia, the brain struggles to maintain its delicate balance.

When myelin breaks down, microglia step in to clear the remnants, preventing further harm. However, the study reveals a troubling consequence: as these cells remove iron-rich myelin, they trigger their own destruction through ferroptosis. This process weakens the brain’s natural defenses and accelerates neurodegeneration.

Researchers had long recognized that iron buildup was linked to cognitive decline, but the direct connection between ferroptosis and microglial loss is a new revelation. This discovery reframes how scientists understand the interplay between iron, inflammation, and neurodegenerative diseases.

To investigate, the OHSU team examined post-mortem brain tissue from dementia patients, analyzing the extent of microglial damage. Their findings suggest that targeting ferroptosis could be a promising strategy for slowing disease progression.

“This is a major finding,” said Dr. Stephen Back, the study’s senior author and an expert in myelin research. His past work focused on developmental delays in premature infants, but these results extend his research into the realm of aging and neurodegeneration.

The innovative technique that made this discovery possible was spearheaded by the study’s lead author, Philip Adeniyi, Ph.D., a postdoctoral researcher in Dr. Back’s laboratory. This cutting-edge method brought into sharp focus the role of microglia in the white matter regions of Alzheimer's and vascular dementia patients' brains.

Dr. Back, reflecting on the significance of these findings, remarked, “We’ve missed a major form of cell death in Alzheimer’s disease and vascular dementia. It’s just amazing that we missed this until now.”

It's a revelation that's set to transform the way we perceive Alzheimer’s and vascular dementia. Co-author Kiera Degener-O’Brien, M.D., was the first to notice microglial degeneration in tissue samples. Building on this, Adeniyi's immunofluorescence technique confirmed that it was iron toxicity from myelin fragments leading to this degeneration. In essence, these immune cells were succumbing while performing their protective functions.

Dr. Back highlighted the previously underestimated role of microglia, saying, “Everyone knows that microglia are activated to mediate inflammation. But no one knew that they were dying in such large numbers.”

These findings have broad implications. The progressive decline of microglia may very well be a driving mechanism behind the cognitive deterioration seen in Alzheimer’s and vascular dementia patients. Recognizing this, Dr. Back anticipates a surge of interest from the pharmaceutical industry.

“That’s where the field will go next,” he asserted, hopeful about the development of compounds targeting microglial degeneration.

The starting point of this degenerative cycle likely roots back to repeated episodes of reduced blood flow and diminished oxygen supply to the brain. Factors such as acute stroke or chronic conditions, including hypertension and diabetes, might be contributing culprits.

Dr. Back concluded with a profound thought, “Dementia is a process that goes on for years and years. We have to tackle this from the early days to have an impact so that it doesn’t spin out of control.”

As we stand on the cusp of this breakthrough, the field of dementia research has received a renewed impetus. This discovery, encapsulating the pivotal role of ferroptosis, presents an untapped reservoir of opportunities for scientists, researchers, and pharmaceutical pioneers. Only time will tell how this newfound knowledge shapes the future of dementia care and therapeutics.

Note: Materials provided above by the The Brighter Side of News. Content may be edited for style and length.

Like these kind of feel good stories? Get the Brighter Side of News' newsletter.